ENZB — Enzo Biochem Balance Sheet
0.000.00%
- $25.67m
- -$14.41m
- $31.91m
- 55
- 62
- 28
- 46
Annual balance sheet for Enzo Biochem, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | R2022 July 31st | 2023 July 31st | 2024 July 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 47.9 | 43.5 | 21.6 | 82.4 | 52.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 9.14 | 10.2 | 4.76 | 4.81 | 3.99 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 68.8 | 70.6 | 42.8 | 98.5 | 70 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 34.4 | 33.6 | 16 | 16.7 | 15.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 113 | 114 | 75.6 | 122 | 85.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 32.8 | 26.1 | 13 | 40 | 24.8 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 54.2 | 45.1 | 21.1 | 43.4 | 29.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 58.4 | 68.6 | 54.5 | 78.5 | 56.1 |
Total Liabilities & Shareholders' Equity | 113 | 114 | 75.6 | 122 | 85.8 |
Total Common Shares Outstanding |